Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788736 · ClinicalTrials.gov registry record
Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism
A clinical trial, sponsored by Ottawa Hospital Research Institute.
- Completed
- Registry status
- 2,537
- Enrollment target
NCT00788736 is a clinical trial that has completed, run by Ottawa Hospital Research Institute. The registered enrollment target is 2,537 participants.
The verdict
NCT00788736 has completed, sponsored by Ottawa Hospital Research Institute.
- COMPLETED
- Registry status
- 2,537 participants
- Enrollment target
Study Summary
The main objective of the study is to develop or validate a clinical prediction rule for major bleeding in patients on oral anticoagulant therapy who have been safely anticoagulated without bleeding or venous thromboembolism (VTE) recurrence for at least 3 months since diagnosis and are being considered for long-term oral anticoagulant therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,537 participants |
| Start Date | 2008-09 |
| Est. Completion | 2016-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00788736
The ClinicalTrials.gov registry entry for NCT00788736 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,537 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ottawa Hospital Research Institute, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00788736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00788736 about?
NCT00788736 is a clinical study titled "Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism". The main objective of the study is to develop or validate a clinical prediction rule for major bleeding in patients on oral anticoagulant therapy who have been safely anticoagulated without bleeding or venous thromboembolism (VTE) recurrence for at least 3 months since diagnosis and are being consid...
What is the current status of trial NCT00788736?
This trial is currently completed. The enrollment target is 2,537 participants. The study started on 2008-09. Estimated completion is 2016-10.
Who is sponsoring clinical trial NCT00788736?
This trial is sponsored by Ottawa Hospital Research Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.